[ad_1]
The Johnson & Johnson vaccine received a green light from Brussels for use in the EU on March 11. It is the fourth crown vaccine after the Biontech / Pfizer, Moderna and Astrazeneca vaccines, which are approved by the entire EU.
Cooperation with European companies
To expand its production, the American company had signed several cooperation agreements with European companies in recent months, including IDT Biologika from Dessau. Johnson & Johnson also works with Sanofi in France and Catalent in Italy.
Johnson & Johnson in the US and South Africa in action
The US company’s vaccine is currently being used in the US and South Africa, and approval has also been granted for Canada. According to the company, the J&J vaccine, which, unlike other vaccines, only needs to be administered once, also protects against coronavirus mutants.
Very effective against steep slopes
A worldwide study with almost 40,000 participants showed an efficacy of 85.4 percent against severe courses of Covid-19, the efficacy with moderate courses was 66 percent. Unlike competing products, the vaccine does not need to be cooled down as much, making it easier to transport and distribute.
(Quelle: What / Afp)
